title: [The double messages about atenolol must be an issue for the SBU board].
authors.affiliation: SBU, Stockholm.
authors.forename: Lars
authors.initials: L
authors.lastname: Werkö
authors.forename: Christer
authors.initials: C
authors.lastname: Enkvist
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use*; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D001262:Atenolol / Q000627:therapeutic use*; D032921:Consensus; D019317:Evidence-Based Medicine; D006801:Humans; D006973:Hypertension / Q000188:drug therapy; D015201:Meta-Analysis as Topic; D017410:Practice Guidelines as Topic; D017594:Publication Bias; D013548:Sweden
chemical_list: D000319:Adrenergic beta-Antagonists; D000959:Antihypertensive Agents; D001262:Atenolol